Cancer Family
Invasive Malignant Neoplasm
CI-CAN-00000213Explore in graph →
604 active trials9 approved drugs37 evidence items
- NCIt
- C8505
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000213Explore in graph →
Clinical trials
1,820 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04539327 | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study | completed | — | 51 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 117 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY |
| 2 |
| Mar 18, 2026 |
| clinicaltrials |
| NCT02779855 | Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT01616875 | Bristol Bladder Trial | completed | Phase 2 | 28 | University Hospitals Bristol and Weston NHS Foundation TrustOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04288687 | A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects | completed | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT01409200 | Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis | completed | Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04610671 | Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06235099 | Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer(Solar-Recur) | completed | Phase 3 | 235 | Curium US LLCINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT02530489 | Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT01517451 | Radiation and Androgen Ablation for Prostate Cancer | completed | Phase 1 / Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT05415215 | A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer(ProHer) | completed | Phase 3 | 346 | Hoffmann-La RocheINDUSTRY | 17 | Feb 10, 2026 | clinicaltrials |
| NCT04457089 | Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer | completed | Early Phase 1 | 18 | Marc GoodmanOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06086665 | The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer(REFIRM) | completed | — | 850 | Asan Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04481113 | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | completed | Phase 1 | 8 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03622385 | Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer | completed | — | 10 | Baylor Research InstituteOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04593277 | Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study | completed | N/A | 549 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT03503344 | Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer(PILLAR) | completed | Phase 2 | 26 | University of California, San FranciscoOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05375903 | A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | completed | Phase 1 | 51 | UroGen Pharma Ltd.INDUSTRY | 3 | Jan 14, 2026 | clinicaltrials |
| NCT04870515 | Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study | completed | N/A | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06173037 | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | completed | Phase 2 | 43 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03212170 | FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer | completed | Phase 2 | 21 | University of Wisconsin, MadisonOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03345420 | Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer(NOVEMBER) | completed | Phase 2 | 102 | University of UtahOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05483933 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | completed | Phase 1 | 86 | Shattuck Labs, Inc.INDUSTRY | 4 | Dec 23, 2025 | clinicaltrials |
| NCT03027479 | Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss(METERMUS-IMC) | completed | N/A | 70 | University Hospital, ToursOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02600156 | Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors | completed | N/A | 7 | Mayo ClinicOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03534947 | A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma(SONIB) | completed | Phase 2 | 16 | Melanoma Institute AustraliaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06870539 | Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment | completed | — | 49 | Mayo ClinicOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04543903 | Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer | completed | N/A | 1 | Alpha Tau Medical LTD.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05630131 | ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy | completed | — | 1 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT03839524 | A Trial Evaluating TG4050 in Ovarian Carcinoma. | completed | Phase 1 | 64 | TransgeneINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT03860961 | Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy | completed | N/A | 550 | NRG OncologyOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT02111941 | Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Early Phase 1 | 19 | Mayo ClinicOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT02203695 | Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | completed | Phase 2 | 86 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT03325634 | Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer | completed | Phase 1 | 15 | University of Colorado, DenverOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT02159989 | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 83 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05293496 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | completed | Phase 1 | 31 | MacroGenicsINDUSTRY | 1 | Oct 14, 2025 | clinicaltrials |
| NCT03914794 | A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05446870 | Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002) | completed | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Oct 1, 2025 | clinicaltrials |
| NCT03516812 | Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer | completed | Phase 2 | 36 | University of WashingtonOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT02186470 | Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer | completed | N/A | 22 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04383743 | Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer | completed | Phase 2 | 17 | University of WashingtonOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05036083 | Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion | completed | N/A | 89 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT01841749 | Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast(CINNAMOME) | completed | — | 228 | Institut BergoniéOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04374630 | Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian(PROFECTA-II) | completed | Phase 2 | 150 | Laekna LimitedINDUSTRY | 2 | Sep 10, 2025 | clinicaltrials |
| NCT02470897 | Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer | completed | N/A | 115 | University of Wisconsin, MadisonOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03085225 | Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.(TRAMUNE) | completed | Phase 1 | 40 | Institut BergoniéOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT02022202 | Breast Cancer Genome Guided Therapy Study (BEAUTY)(BEAUTY) | completed | — | 140 | Mayo ClinicOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT02498600 | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 100 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 18, 2026source: clinicaltrials